0.15Open0.15Pre Close0 Volume183 Open Interest290.00Strike Price0.00Turnover3344.44%IV17.82%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.0214Delta0.0026Gamma1641.80Leverage Ratio-224.2779Theta0.0000Rho35.09Eff Leverage0.0003Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet